These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 22515658

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
    Yim KL.
    Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
    [Abstract] [Full Text] [Related]

  • 3. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S.
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [Abstract] [Full Text] [Related]

  • 4. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D, Spada F, Lambrescu I, Rubino M, Cella C, Gibelli B, Grana C, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, Fazio N, IEO ENETS Center of Excellence for GEP NETs.
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L, Schwarz RE.
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. New targeted agents in gastroenteropancreatic neuroendocrine tumors.
    Benavent M, de Miguel MJ, Garcia-Carbonero R.
    Target Oncol; 2012 Jun; 7(2):99-106. PubMed ID: 22585431
    [Abstract] [Full Text] [Related]

  • 9. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG, Strosberg JR, Halfdanarson TR.
    Oncology; 2012 Jun; 83(3):117-27. PubMed ID: 22797357
    [Abstract] [Full Text] [Related]

  • 10. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R, Lang B, Wong H, Chiu J, Yat WK, Shek T, Cho WY, Yau LC, Yau T.
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [Abstract] [Full Text] [Related]

  • 11. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors.
    Phan AT, Dave B.
    Cancer Med; 2016 Oct; 5(10):2953-2964. PubMed ID: 27539383
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Neuroendocrine tumors: the age of targeted therapies].
    Capdevila J, Argilés G, Mulet-Margalef N, Tabernero J.
    Endocrinol Nutr; 2012 Oct; 59(7):438-51. PubMed ID: 22565119
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N, Reidy-Lagunes D.
    Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
    [Abstract] [Full Text] [Related]

  • 16. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
    Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E.
    BMJ Open; 2015 May 19; 5(5):e008248. PubMed ID: 25991462
    [Abstract] [Full Text] [Related]

  • 17. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors.
    Beyens M, Vandamme T, Peeters M, Van Camp G, Op de Beeck K.
    Endocr Relat Cancer; 2019 Mar 01; 26(3):R109-R130. PubMed ID: 32022503
    [Abstract] [Full Text] [Related]

  • 18. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN, Syrigos KN, Saif MW.
    JOP; 2014 Jul 28; 15(4):351-3. PubMed ID: 25076341
    [Abstract] [Full Text] [Related]

  • 19. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L, Paganelli G, Delle Fave G, de Braud F.
    Cancer Treat Rev; 2010 Nov 28; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [Abstract] [Full Text] [Related]

  • 20. Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
    Reidy-Lagunes D, Thornton R.
    Curr Oncol Rep; 2012 Jun 28; 14(3):249-56. PubMed ID: 22434313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.